Sam Brown Healthcare Communications’ Post

Briefly Bio launches with $1.2m Pre-Seed Funding to Make Complex Lab Experiments Reproducible Briefly Bio, a biotech startup simplifying complex lab processes, has launched with $1.2 million in pre-seed funding. Co-founded in 2022 by Harry Rickerby, Katya Putintseva, and Staffan Piledahl, the company has launched innovative software to make lab work easily reproducible. It allows scientists to capture their work clearly and share it consistently. According to the company’s announcement reported by Health Tech Digital, the pre-seed round was spearheaded by Compound VC, with a significant contribution from Tiny VC, NP-Hard Ventures, and multiple angel investors from the biotechnology and technology sectors. Read more: https://lnkd.in/gwnd-Jzt #fundingnews #FundingOpportunity #StartupFunding #PreSeed #StartupSuccess #HealthcareNews #LabTechnology #HealthcareFunding #nextdigitalhealth #Wi4 #vineetagrawal

Cellivate Technologies, a promising biotech startup, has successfully secured $1 million in a seed funding round led by Antler, with additional participation from Venture Catalysts++ | India's 1st Multi-Stage VC, Hatcher+, and We Founder Circle. This crucial infusion of capital is set to propel the company’s research and development (R&D) efforts, scale up production of its groundbreaking products, and broaden its market reach, as announced in a recent press release. Founded by Viknish Krishnan-Kutty, PhD, Cellivate Technologies is on a mission to tackle some of the most pressing challenges in cell culture and biomanufacturing. The company is renowned for its flagship products, which include advanced microcarriers designed to enhance cell growth and a novel cell-based serum intended to replace the traditional fetal bovine serum (FBS). These innovations promise to revolutionize the biomanufacturing industry by offering more efficient, cost-effective, and ethical solutions. #startup #startupinvestment #biotechnology #startupnews

We had a great session today with Zoe Yu Tung Law co-founder and CEO of New Wave Biotech Many thanks to Zoe for being so open and honest about the highs and lows of being an entrepreneur and starting a family. What did we learn? 💪 Do what you believe in as that's what will carry you through the tough times. 👩💻 You don't need to be a technical expert to start an amazing company - you need to define the challenge and then find the right people with the right expertise to help you get there. 🤱 Babies are very good for honing time management skills. 👶 Being prepared is the only way forward in motherhood - and always prepare for the unexpected. 👯 Work hard to build a supportive network around you AND also around those that love and support you. 🙋♀️ Some VCs need to stop being prejudiced about female founders having kids. Get real folks. Life happens. 😇 And don't beat up on yourselves ladies. Being good enough is sometimes just good enough.

𝐌𝐞𝐥𝐛𝐨𝐮𝐫𝐧𝐞 𝐡𝐚𝐬 𝐚 𝐧𝐞𝐰 𝐛𝐢𝐨𝐢𝐧𝐜𝐮𝐛𝐚𝐭𝐨𝐫, 𝐛𝐮𝐭 𝐰𝐡𝐚𝐭 𝐝𝐨𝐞𝐬 𝐭𝐡𝐢𝐬 𝐦𝐞𝐚𝐧 𝐟𝐨𝐫 𝐢𝐭𝐬 𝐠𝐫𝐨𝐰𝐢𝐧𝐠 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 𝐩𝐫𝐞𝐜𝐢𝐧𝐜𝐭? 𝐀𝐧𝐝 𝐰𝐡𝐨 𝐚𝐫𝐞 𝐭𝐡𝐞 𝐰𝐢𝐧𝐧𝐞𝐫𝐬 𝐚𝐬 𝐚 𝐫𝐞𝐬𝐮𝐥𝐭?   Come find out who the new kid on the block is at CSL headquarters. The collaborative triple threat between Unimelb, WEHI, and CSL is sure to shake up the current landscape and further develop the biotechnological advancements of Australian startups. https://lnkd.in/gYepAGZH

🔓 𝐔𝐧𝐥𝐨𝐜𝐤! If you’re leading an early-stage biotech start-up and have a groundbreaking idea, 𝘵𝘩𝘦 𝘰2𝘩 𝘒𝘪𝘤𝘬𝘴𝘵𝘢𝘳𝘵𝘦𝘳: 𝘐𝘯𝘯𝘰𝘷𝘢𝘵𝘦 𝘈𝘮𝘦𝘳𝘪𝘤𝘢 competition can be your opportunity to get the support and expertise needed to boost your novel drug discovery program. 🤷♀️ As an early-stage biotech startup, you might often encounter a range of challenges, from limited funding and complex regulatory and inventory requirements to scientific hurdles, intense competition, and the demands of managing time and resources. 👨🔬 To address these challenges and provide essential support to early-stage biotech startups like yours, o2h Discovery has relaunched its latest edition, “Innovate America.” To read more about the competition and to apply to get a benefit, please visit: https://lnkd.in/dAxrjKjn or to apply, visit - https://lnkd.in/deKVkyYU #USA #BiotechStartups #InnovativeIdeas #o2hKickstarter #SeedingNewIdeas #AmericanBiotech #DrugDiscovery #Award #Competition

Latest DON Therapeutics news. Excited to witness the remarkable growth of biotech startups, paving the way for groundbreaking innovations that are reshaping our world. These trailblazing ventures embody the essence of entrepreneurship, driving forward advancements in healthcare, agriculture, and beyond. It’s inspiring to see how these startups are leveraging cutting-edge technology and scientific expertise to address pressing global challenges. At the heart of their success lies strategic partnerships and robust funding support. Collaboration with industry leaders, research institutions, and investors plays a pivotal role in accelerating their journey from ideation to implementation. By forging strong alliances, biotech startups gain access to invaluable resources, expertise, and networks, propelling them towards transformative breakthroughs. For more information check out our DON Therapeutics website tailored for CEOs and decision makers within biotech: https://lnkd.in/eKs-9g9e We are always on the look out for new biotech opportunites. Let us assist you by submitting your opportunity via this link - https://lnkd.in/dcvSMynH #biotech #funding #strategicpartnerships #ceos #introduction

Vol 8 -Newsletter of Investingintalent #startups #funding

A great read from Nature Portfolio about co-working labs for #biotech #startups. The article explores how shared lab spaces enhance startup growth by fostering a sense of community, providing access to mentors and saving costs. STEMCELL Technologies #biotechinnovation #biotechrevolution #coworkinglabs #collaborativeresearch #labspace #startupcommunity #innovationinscience #startupsuccess

Latvian #biotech Cellbox Labs, which develops #industrial organ-on-chip technology, has raised €935K in a pre-seed round, led by Latvian Buildit VC, with participation from a syndicate of 12 LatBAN’s angels, managed by Girts Licis, Latvian investment fund ASP Asset Management AIFP, and its owner Ansis Spridzans. Founded in 2020 in #Riga by Arturs Abols, Gatis Mozolevskis, and Roberts Rimša, Cellbox Labs develops an organ-on-chip technology, which is based on the creation of miniature replicas of human organs (gut, lung) outside of the human organism, thus reducing animal testing in #research. These replicas can be used to test various biological processes and for drug development. This technology allows for more accurate predictions of a drug's efficacy and toxicity during the development phase. Additionally, Cellbox Labs is developing an automated organ-on-chip cultivation device that ensures high productivity, reduces the impact of human error, and minimizes the need for manual intervention. The startup will use the investment to complete the first version of this device and begin sales. Buildit is an accelerator for hardware and IoT startups. It provides €10K to €50K of pre-seed investments to best-performing startups and up to €250K of seed investments. Buildit's partners are Matiss Neimanis, Rene Tõnnisson, and Aleksander Tõnnisson. Read more https://lnkd.in/ekMDDUEn #Latvia #startup #startups #tech #technology #technologies #TechnologyNews #TechNews #Deal #Deals #VentureCapital #VC #MedTech